A Prospective Case Series Analysis of Initial Users of the Urovac Device

Sponsor
Cedars-Sinai Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT03872518
Collaborator
Dignity Medical Solutions (Other), California Rehabilitation Institute (Other)
30
1
29.5
1

Study Details

Study Description

Brief Summary

To document usage of the Urovac device among 30 initial users of the device in an acute rehabilitation facility, with analysis of whether and how patients benefitted, challenges encountered, and how benefits and challenges varied by patient type.

Condition or Disease Intervention/Treatment Phase
  • Device: Urovac

Detailed Description

The Urovac device holds the promise of improving care for many of these patients in a manner that may also significantly decrease costs. The aim of the study is to determine if this device may increase quality of life for patients by reducing urine spills, reducing falls by avoiding urgent situations where patients try to ambulate to the bathroom to avoid wetting sheets, reducing skin breakdown by avoiding urine spills, reducing excoriation of the glans penis, and reducing urinary tract infections.

The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. There is also a removable cloth-covered platform to reduce spills. Allowing for the evacuation of urine from the urinal significantly improves its functionality. The Urovac can be left in place without risk of overflow or other spillage, such that a patient with UI requires less assistance. Improving the handheld urinal in this manner should thus allow for reduced usage of diapers, catheterization, and institutionalization. For patients with UI requiring hospitalization or institutionalization for other reasons, the Urovac could potentially reduce the associated labor and complication costs. Despite the clear clinical promise of the Urovac, it has only been used by a small number of patients to date. This study will document usage of the Urovac among 30 of the initial users of the device to better understand the benefits and challenges.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Prospective Case Series Analysis of Initial Users of the Urovac Device
Actual Study Start Date :
Apr 17, 2019
Anticipated Primary Completion Date :
Jun 30, 2021
Anticipated Study Completion Date :
Sep 30, 2021

Outcome Measures

Primary Outcome Measures

  1. Patient satisfaction with Urovac device: 5-point scale [24 hours after patient is given instructions on how to use Urovac device.]

    Patient satisfaction with the Urovac device after two-hour use of the device, as measured by the statement: "I would recommend it to someone in a similar situation." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

  2. Patient perception of urine spills after using Urovac [24 hours after patient is given instructions on how to use Urovac device.]

    Patient perception of urine spills after using Urovac after two-hour use of the device, as measured by the statement: "Urovac helped to avoid urine spills ." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

  3. Patient perception of dignity preservation after using Urovac [24 hours after patient is given instructions on how to use Urovac device.]

    Patient perception of dignity preservation after using Urovac after two-hour use of the device, as measured by the statement: "Urovac helped preserve dignity." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

  4. Patient perception of ulcer prevention [24 hours after patient is given instructions on how to use Urovac device.]

    Patient perception of ulcer prevention after using Urovac after use of the device, as measured by the statement: "Urovac helped avoid decubitus ulcers, or helped keep them dry." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

  5. Patient perception of reduced risk of falls [24 hours after patient is given instructions on how to use Urovac device.]

    Patient perception of reduced risk of falls after using Urovac after use of the device, as measured by the statement: "Urovac helped reduce risk of falls related to getting to a toilet." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

  6. Patient perception of caregiver time spent on helping patient use bathroom [24 hours after patient is given instructions on how to use Urovac device.]

    Patient perception of caregiver time spent on helping patient use bathroom after using Urovac after use of the device, as measured by the statement: "Urovac helped save patient/caregiver time." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

  7. Clinician perception of Urovac effectiveness in avoiding foley catheterization or condom catheter [24 hours after patient is given instructions on how to use Urovac device.]

    Clinician perception of Urovac effectiveness in avoiding foley catheterization or condom catheter, as measured by the statement: "Urovac helped patient to avoid foley catheterization or condom catheter." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

  8. Clinician perception of Urovac effectiveness of decreasing development or severity of decubitus ulcers. [24 hours after patient is given instructions on how to use Urovac device.]

    Clinician perception of Urovac effectiveness of decreasing development or severity of decubitus ulcers, as measured by the statement: "Urovac helped patient with decubitus ulcers." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

  9. Clinician perception of Urovac effectiveness of decreasing risk of falls when going to the toilet [24 hours after patient is given instructions on how to use Urovac device.]

    Clinician perception of Urovac effectiveness of risk of falls when going to the toilet, as measured by the statement: "Urovac helped reduce risk of falls related to getting to a toilet." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

  10. Clinician perception of Urovac effectiveness of decreasing risk of hospitalization or skilled nursing facility [24 hours after patient is given instructions on how to use Urovac device.]

    Clinician perception of Urovac effectiveness of decreasing risk of hospitalization or skilled nursing facility, as measured by the statement: "Urovac helped patient avoid hospitalization or skilled nursing facility admission." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

  11. Clinician satisfaction with Urovac device: 5-point scale [24 hours after patient is given instructions on how to use Urovac device.]

    Clinician satisfaction with Urovac device, as measured by the statement: "I would recommend it to a physician colleague." The 5-point scale goes from 1-5, with 1 being "strongly disagree," 2 being "somewhat disagree," 3 being "neither agree nor disagree," 4 being "somewhat agree," and 5 being "strongly agree."

Secondary Outcome Measures

  1. Development of urinary tract infection after using Urovac [24 hours after patient is given instructions on how to use Urovac device.]

    Development of urinary tract infection after using Urovac, dichotomous measure (yes/no) measured by checking electronic health record for evidence of urinary tract infection after use of the device.

  2. Average hours of daily use of Urovac by patient [24 hours after patient is given instructions on how to use Urovac device.]

    Average hours of daily use of Urovac by patient

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Male patients who identify as having difficulty with functional urinary incontinence, such that it may be difficult to get to the toilet in time to urinate

  • Patients age 18 or older

Exclusion Criteria:
  • Patients with leg wounds or dysfunction which could be worsened by Urovac device placement

  • Patients under age 18

Contacts and Locations

Locations

Site City State Country Postal Code
1 California Rehabilitation Institute Los Angeles California United States 90067

Sponsors and Collaborators

  • Cedars-Sinai Medical Center
  • Dignity Medical Solutions
  • California Rehabilitation Institute

Investigators

  • Principal Investigator: Joshua Pevnick, MD, Cedars-Sinai Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Josh Pevnick, Assistant Professor of Medicine and Associate Director, Division of Informatics, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
NCT03872518
Other Study ID Numbers:
  • Pro00049729
First Posted:
Mar 13, 2019
Last Update Posted:
Oct 29, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 29, 2020